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doi:10.101High Rabbit-Antihuman Thymocyte Globulin Levels Are
Associated with Low Likelihood of Graft-vs-Host
Disease and High Likelihood of Posttransplant
Lymphoproliferative Disorder
Peter J. Podgorny, Alejandra Ugarte-Torres, Yiping Liu, Tyler S. Williamson,
James A. Russell, Jan StorekRabbit-antithymocyte globulin (ATG) given with conditioning has the potential to decrease the likelihood of
graft-versus-host disease (GVHD) or graft failure and to increase the likelihood of relapse or infections. After
a given ATG dose, serum ATG levels are variable. Here we determined ATG levels on days 7 and 28 in 153
patients whose conditioning included 4.5 mg/kg ATG (thymoglobulin). Median follow-up was 547 days (range:
14-1519, minimum for patients who have not died, relapsed, developed second malignancy, or had graft failure,
365). Both high day 7 levels and high day 28 levels were associated with low likelihoods of grade II-IV acute
GVHD and chronic GVHD needing systemic immunosuppressive therapy, and a high likelihood of posttrans-
plant lymphoproliferative disorder (PTLD). Patients with day 7 ATG levels above 0.803 mg/L had 0.52-fold risk
of developing chronic GVHD needing systemic therapy (P5 0.012) and patients with day 7 ATG levels above
1.436 mg/L had 5.84-fold risk of developing PTLD (P5 0.001) compared to patients with lower ATG levels.
There was no association of ATG levels with relapse, death, or non-PTLD infections. Association with graft
failure could not be evaluated due to only 4 graft failures in the cohort. In conclusion, patients with slow clear-
ance of ATG have a low risk of GVHD, but a high risk of PTLD. The clearance of this relatively low dose of ATG
does not impact the likelihood of relapse, death, or non-PTLD infections.
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Rabbit-antithymocyte globulin (ATG) has been
increasingly used as a component of allogeneic hema-
topoietic cell transplant (HCT) conditioning [1-9].
Two prospective randomized studies, comparing
either rabbit-antihuman T cell line (Jurkat) globulin
(ATG-F, Fresenius, Phoenix, AZ) versus no ATG
[10] or rabbit-antihuman thymocyte globulin (Thy-
moglobulin, Genzyme, Phoenix, AZ) versus no
ATG [11], showed that ATG results in decreasedThe University of Calgary and Alberta Health Services,
ry, Alberta, Canada.
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disease (aGVHD, cGVHD) and thus presumably
improved quality of life, without having a significant
impact on malignancy relapse, nonrelapse mortality
(NRM), relapse-free survival (RFS), or overall survival
(OS). Of note, no anti-GVHD effect was observed in
a prospective randomized study evaluating horse-
antihuman thymocyte globulin (Atgam, Upjohn,
Kalamazoo, MI) [12], which is not the subject of this
article. On another note, the anti-GVHD activity of
rabbit ATG is present if used prophylactically, but
may be minimal or absent if used therapeutically [13].
The mechanism of anti-GVHD effect of rabbit
ATG is complex and not completely understood
[14]. The antibodies within ATG are polyclonal, and
target antigens expressed on not only T cells but also
other hematolymphatic cells that may be involved in
the pathogenesis of aGVHD or cGVHD, like
dendritic cells or B cells. The antibodies may kill the
targeted immune cells (inducing apoptosis, natural
killer [NK] cell-mediated lysis, or complement-
mediated lysis) or alter their function (inducing
T cell differentiation into regulatory cells, inhibiting915
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needed for interaction with other cells or chemotaxis)
[15-17]. When ATG is given during conditioning, not
only recipient but also donor immune cells are
depleted or inhibited, as the serum half-life of ATG
is 1-6 weeks [16,18-24]. ATG may kill not only
immune cells, but also some leukemic cells [25].
Theoretically, ATG should minimize the likeli-
hood of graft failure, as ATG should kill or inhibit
recipient T cells that mediate graft rejection and not
donor hematopoietic stem cells [25]. However, in the
prospective randomized studies the incidence of graft
failure appeared similar between the ATG and
non-ATG arms, but the number of patients with graft
failure was too small for a meaningful analysis [10,11].
In a retrospective study, the incidence of graft failure
was lower with versus without thymoglobulin [26].
Theoretically, ATG should also increase the likeli-
hood of infections, as ATG should kill or inhibit donor
or recipient pathogen-specific T cells and other
immune cells. However, in the randomized study eval-
uating ATG-F there was no difference in the rates of
microbiologically documented infections [10]. There
was a trend toward higher rates of presumed (not
microbiologically documented) infections in the
ATG-F armcompared to the no-ATGarm, and among
microbiologically documented infections, there was
a trend toward higher rates of herpes simplex virus dis-
ease, cytomegalovirus (CMV) reactivation (not CMV
disease), and Epstein-Barr virus (EBV)-associated
posttransplant lymphoproliferative disorder (PTLD).
In the randomized study evaluating thymoglobulin,
there was an increased incidence of fatal infections in
a subgroup receiving 15 mg/kg, but not in a subgroup
receiving 7.5 mg/kg compared to no ATG [11]. The
fatal infectionswere bacterial or fungal. CMV reactiva-
tion did not appear to be increased, and no PTLD is
mentioned in the article.
Collectively, ATG has been shown to reduce the
likelihood of aGVHD and cGVHD; however, its
impact on graft failure and infections (including
PTLD) is unclear. Here we set out to determine the
impact of ATG on clinical outcomes including infec-
tions. We took advantage of the fact that there is
amarked interpatient variability inATGclearance (dif-
ferent serum ATG levels are detected after the same
dose of ATG) [20,22], and that we were able to study
a relatively homogeneous patient group given the
same conditioning, including the same dose of ATG.PATIENTS AND METHODS
Patients and Transplantation
We studied 153 consecutive recipients of alloge-
neic HCT performed in Calgary who received ATG
as a part of their conditioning and consented to donateblood for research on day 7 and day 28. The
transplants were performed between December 2004
and September 2008. Patients typically received
conditioning with fludarabine (250 mg/m2), busulfan
(approximately 13 mg/kg i.v., pharmacokinetically
adjusted) and ATG, and additional GVHD prophy-
laxis with methotrexate on days 1, 3, 6, and 11 and
cyclosporine from day 21 until 3 to 6 months
posttransplant (longer in the case of cGVHD) [8].
Conditioning of some patients included total body
irradiation (TBI) (4 cGy) [27]. All patients received
ATG (thymoglobulin, Genzyme) 0.5 mg/kg on day
22, 2.0 mg/kg on day21, and 2.0 mg/kg on day 0 (to-
tal, 4.5 mg/kg) [8]. Table 1 displays patient and donor
characteristics. Supportive care was similar for all
patients. All blood products were from CMV seroneg-
ative donors and were leukocyte depleted. No antibac-
terial or antifungal prophylaxis was given routinely
(except for trimethoprim-sulfamethoxazole for Pneu-
mocystis prophylaxis). Pneumocystis prophylaxis, typ-
ically using trimethoprim-sulfamethoxazole, was given
until 6 months posttransplant or longer (in the case of
cGVHD needing systemic therapy). Acyclovir, typi-
cally 400 mg twice a day orally, was used until 6-12
months posttransplant or longer (in the case of
cGVHD needing systemic therapy). Monitoring of
EBV DNAemia was not done. Median follow-up was
547 days (range: 14-1519 days; minimum for patients
who have not died, relapsed, developed second
malignancy or had graft failure, 365 days).
Fourty-eight autologous HCT recipients (who
received no ATG) were used as controls for the
determination of ATG serum level detection limit.Determination of ATG Levels
Blood was scheduled to be drawn from patients on
approximately day 7 and 28 posttransplant. The actual
median day of the day 7 blood draw was day 7 (range:
6-8), and the actual median day of the day 28 blood
draw was day 28 (range: 23-34). The ‘‘day 7’’ blood
draw was performed on 115 patients and the ‘‘day
28’’ blood draw on 137 patients. Serum was separated
from the blood and kept in tightly sealed vials at minus
80C until ATG level determination.
Level (concentration) of ‘‘functional’’ ATG (capa-
ble of binding to human lymphocytes) was determined
using the method of Kakhniashvili et al. [22] with
minor modifications. To prepare standards of known
ATG concentration, ATG (thymoglobulin, Genzyme)
was diluted in normal human serum to a concentration
of 20 mg/L. This was serially 2-fold diluted to produce
a range of ATG standards ranging from 20 to 0.0098
mg/L. Peripheral blood mononuclear cells (drawn
from 1 individual at 1 time to minimize assay variabil-
ity) were separated from heparinized blood using den-
sity gradient centrifugation (Lympholyte, Cedarlane
Table 1. Patient Characteristics
N 153
Median patient age 49 (range, 19-66)
Median donor age 36 (range, 15-67)
Patient sex 91 M, 62 F
Donor sex 99 M, 54 F
Diagnosis/disease stage at transplant*
Poor risk 73
Good risk 80
Diagnosis
AML in first remission 42
AML beyond first remission 20
ALL in first remission 13
ALL beyond second remission 7
CML in first chronic/accelerated phase 10
CML in blast or second chronic/
accelerated phase
2
CMML 5
CLL 10
Non-Hodgkin lymphoma 21
Hodgkin lymphoma 2
Myelodysplastic syndrome/
myelofibrosis
15
Aplastic anemia 3
Other 3
Stem cell source
Bone marrow 10
Blood stem cells 143
Donor/Recipient CMV serostatus at HCT
Positive/positive 45
Positive/negative 14
Negative/positive 34
Negative/negative 59
Unknown or indeterminate 1
Donor/Recipient EBV serostatus at HCT
Positive/positive 131
Positive/negative 5
Negative/positive 9
Negative/negative 0
Unknown or indeterminate 8
Conditioning with TBI
Yes 96
No 57
Donor type
HLA-matched sibling 76
Other† 77
Graft failure
Primary 3
Secondary 1
PTLD
Yes 14
No 139
Acute GVHD by grade
None 73
Grade 1 41
Grade 2 23
Grade 3 14
Grade 4 2
Chronic GVHD
None 58
NNST‡ 13
NST‡ 54
Not-evaluable
(end of FU before day 100)
28
AML indicates acute myelogenous leukemia; ALL, acute lymphoid leuke-
mia; CML, chronic myelogenous leukemia; CMML, chronic myelomono-
cytic leukemia; CLL, chronic lymphocytic leukemia; GVHD, graft-versus-
host disease; PTLD, posttransplant lymphoproliferative disorder; TBI, total
body irradiation; HCT, hematopoietic cell transplant; EBV, Epstein-Barr vi-
rus; CMV, cytomegalovirus; FU, follow up.
*Good risk disease was defined as acute leukemia in first remission,
chronic myelogenous leukemia in first chronic or accelerated phase,
myelodysplastic syndrome with <5% marrow blasts or aplastic anemia.
All other diseases/disease stages were considered poor risk.
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mL phosphate-buffered saline (PBS) were added to
20 mL patient serum or ATG standards. After a 30-
minute incubation at room temperature and 3 washes
in PBS, the cells, now coated with ATG, were labeled
with phycoerythrin (PE)-conjugated goat-antirabbit
IgG (Sigma-Aldrich, St. Louis, MO). To accomplish
this, 20 mL PBS containing 0.5 mg of the antibody
was added to the cells and incubated at room temper-
ature in the dark. After 2 washes with PBS, flow cyto-
metric analysis was performed on FACSAria (BD
Biosciences, San Jose, CA). Lymphocytes were gated
by forward and side scatter characteristics. PE fluores-
cence was measured for each standard (Figure 1A) and
for each patient serum included in the run. Titration
curve was generated by plotting ATG level versus
median channel of PE fluorescence intensity
(Figure 1B). Patient ATG levels were extrapolated
from the curve, using the equation y 5 a $ xb .The
numbers for a and b were produced by power regres-
sion using Microsoft Excel software. All patient serum
samples were analyzed twice (2 different runs). The
average of the 2 values was used for analysis. The assays
were run by P.J.P., who was blinded to the patient
outcomes.
Coefficients of variation for the low, middle, and
high ends of the standard curve were calculated based
on 10 experiment repeats, using sera with low ATG
level, intermediate ATG level, and high ATG level.
The coefficient of variation for the low level serum
was 0.26, for the intermediate level serum 0.22, and
for the high level serum 0.15.
Detection limit of the assay was calculated as the
90th percentile of values obtained from measuring
ATG levels in day 7 and/or 28 sera from 48 autologous
HCTrecipients.Thedetection limitwas 0.00131mg/L.
In the allogenic HCT recipients, values under the
detection limit were arbitrarily assigned a level of
0.00066 mg/L (half of the detection limit).Definitions of Outcomes
Relapse, death, nonrelapse death, and graft failure
were defined using standard criteria. aGVHD and
cGVHD were diagnosed according to historical crite-
ria (aGVHD if onset by day 100, cGVHD if present
after day 100). aGVHD was graded according to the
1994 consensus conference [28]. aGVHD-related
death was defined as nonrelapse death occurring in
the first 100 days in a patient with grade II-IV
aGVHD. cGVHD was graded as none, not needing
systemic therapy (‘‘cGVHD NNST’’) or needing†Matched unrelated donors (n551), mismatched donors (n526).
‡NNST indicates ‘‘not needing systemic therapy’’ and NST indicated
‘‘needing systemic therapy.’’
Figure 1. Determination of ATG level. (A) Phycoerythrin fluorescence
peaks, each corresponding to a standard ATG concentration. X-axis
shows phycoerythrin fluorescence intensity area (PE-A). Y-axis shows
the percent maximum cell count (of lymphocytes acquired for each
ATG concentration). (B) Example of a standard curve.
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considered treated (rather than prophylaxed) with
systemic immunosuppressive drugs if cyclosporine
was given beyond 6 months and/or additional
immunosuppressive drug(s) was (were) given at any
time after 3 months posttransplant for treatment of
cGVHD. cGVHD-related death was defined as non-
relapse death occurring after day 100 while the patient
was still treated with systemic immunosuppressive
drugs for cGVHD.
Definite infection was defined as an illness with
symptoms and signs consistent with an infection and
microbiological documentation of a pathogen. For
zoster, clinical diagnosis was considered sufficient.
Microbiological documentation included isolation of
the pathogen by culture from a sterile site or a nonster-
ile site (if from a nonsterile site, the organism had to be
clinically judged as pathogenic) or histological/immu-
nohistological evidence. Culture-documented viremia,
bacteremia, or fungemia was counted even in the
absence of symptoms or signs of infection, except for
Micrococcus or non-JK Corynebacterium, unless
clinically clearly judged as pathogens.
Presumed infection (without an identified micro-
organism) was defined as illness with symptoms and
signs consistent with an infection. However, presumed
oral, gastrointestinal, conjunctival, and respiratory
tract infections were discounted because they could
not be reliably distinguished from GVHD or allergy.
Fever without other symptoms/signs was also
discounted as it could not be reliably attributed to an
infection. Hemorrhagic cystitis was discounted
because it could not be differentiated from condition-
ing regimen-induced cystitis. Sinusitis and pneumonia
were counted only if radiologically documented.
A recurrent infection was counted as multiple
infections if the episodes were separated by .4-week
asymptomatic period. A chronic infection (with
asymptomatic periods lasting #4 weeks) was counted
as 1 infection. A polymicrobial infection of 1 organ
or several adjacent organs was counted as 1 infection.
An infection in $2 nonadjacent organs because of
the same microorganism was counted as 1 infection
(disseminated).
Death because of an infection was defined as (1)
autopsy findings consistent with an infection and the
detection of the pathogen in autopsy specimen, or (2)
death that followedan infection thatwas judged to cause
the death either directly (eg, severe pneumonia) or
indirectly (eg, sepsis with subsequent adult respiratory
distress syndrome).
PTLD was counted as a viral infection. It was
defined as an illness with signs or imaging results
consistent with PTLD (eg, fever not because of other
causes, lymphadenopathy, splenomegaly, or a mass)
with EBV DNA above 10,000 copies/mg leukocyte
DNA or immunohistological evidence of PTLD.PTLD was typically treated with rituximab, with or
without taper of immunosuppressive drug(s).
Statistics
ATG levels in patients with versus without a clini-
cal outcome were compared using Mann-Whitney-
Wilcoxon test. For outcomes for which ATG levels
appeared to be significantly different between patients
with versus without that outcome (P# 0.15), we deter-
mined whether patients with higher than cutoff ATG
levels had a higher/lower likelihood of the outcome
compared to patients with lower than cutoff ATG
levels, using binomial regression models (multivariate
analysis adjusting for confounding factors known to be
associated with the outcome). For each outcome,
a suitable cutoff was determined from a receiver-
operator characteristic (ROC) curve, using the point
with maximum sum of sensitivity and specificity.
Confounding factors (covariates) considered in the
multivariate analyses for aGVHD were recipient age
(continuous), donor type (HLA-matched sibling
versus other), donor/recipient sex (M/M versus other),
recipient CMV serostatus (positive versus negative)
and conditioning regimen (with versus without TBI).
For cGVHD, we considered the same covariates,
plus stem cell source (marrow versus blood stem cells).
For PTLDwe considered donor/recipient EBV seros-
tatus (1/1 versus other including unknown), aGVHD
(grade II-IV) and/or cGVHD (NST) before PTLD
Figure 2. ATG levels in patients with selected clinical outcomes. Horizontal bars indicate median values. NNST indicates ‘‘not needing systemic
therapy’’ and NST indicates ‘‘needing systemic therapy.’’ P-values shown are from the Mann-Whitney-Wilcoxon rank-sum test (univariate analysis).
N.S. indicates nonsignificant or no trend toward significance (P . .15).
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ling versus other), and recipient age (continuous)
[29,30]. Analysis was performed using STATA
software, version 9.2.RESULTS
Median day 7 ATG levels were 1.109 mg/L (range,
undetectable to 4.401 mg/L) and median day 28 levels
were 0.053 mg/L (range, undetectable to 0.733 mg/L).
After plotting ATG levels for patients with differ-
ent grades of aGVHD (Figure 2), it appeared that themedians were similar in patients with grade 0 and I and
lower than those in patients with grade II, III, and IV.
Therefore, and because grade II-IV aGVHD is clini-
cally significant (treated with systemic immunosup-
pressive drugs), we primarily compared ATG levels
in patients with grade 0 or I versus grade II, III, or
IV aGVHD. The latter patients had significantly
lower ATG levels (P 5 0.019 and 0.002 for days 7
and 28, respectively) (Table 2 and Figure 2). We also
compared ATG levels in patients with no aGVHD
versus any aGVHD; ATG levels appeared higher in
the latter group (P 5 0.181 and .021 for days 7 and
28, respectively) (Table 2). We also compared ATG
Figure 2. (continued).
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IV or associated with death) versus all other patients;
the differences were not significant (Table 2).
When plotting ATG levels for patients with no
cGVHD, cGVHD NNST, or cGVHD NST
(Figure 2), it appeared that the medians were similar
in patients with cGVHDNNST andNST, and higher
in patients with no cGVHD.This differencewas signif-
icant (P 5 0.002 and 0.019 for days 7 and 28, respec-
tively) (Table 2). Nevertheless, our primary
comparison was that of ATG levels in patients with no
cGVHD or cGVHD NNST versus cGVHD NST, as
cGVHD NST is clinically significant. The latter
patients tended to have lower ATG levels (P 5 0.025
and 0.148 for days 7 and 28, respectively) (Table 2andFigure 2).Wealso comparedATGlevels inpatients
with cGVHD-associateddeath versus all other patients;
the differences were not significant (Table 2). We also
compared ATG levels in patients with any aGVHD or
cGVHD-associated death versus all other patients;
the differences were also not significant (Table 2).
There was no significant difference in ATG levels
between patients who did versus did not develop graft
failure (but only 4 patients developed graft failure),
relapse, death, nonrelapse death (excluding patients
with relapse from analysis), death because of an infec-
tion (excluding patients with relapse from analysis),
or patients who survived without relapse versus those
who died or relapsed (Table 2). Also, there was no
significant difference in day 7 ATG levels between
Biol Blood Marrow Transplant 16:915-926, 2010 921ATG Levels Associated with GVHD and PTLDpatients who had no versus at least 1 infection between
day 7 and 28, day 7 and 56, or day 7 and 365, and no sig-
nificant difference in day 28 ATG levels between pa-
tients who had no versus at least 1 infection between
day 28 and 56 or day 28 and 365 (Table 2;only data
for the infections between the day of ATG level deter-
mination and day 365 are shown). This was also true
when the analyses were done separately for microbio-
logically documented infections, viral infections,
bacterial infections, and fungal infections. However,
there was a significant difference in both day 7 and
day 28 ATG levels in patients who did versus did not
develop PTLD; patients who developed PTLD had
higher ATG levels (P 5 0.039 and 0.014 for days 7
and 28, respectively) (Table 2 and Figure 2). The me-
dian onset of PTLD was day 57 (range: 38-229). Of
the 14 cases of PTLD, 3 were fatal. There was a trend
toward higher ATG levels in patients with fatal PTLD
than those with nonfatal PTLD (median 1.454 versus
1.100 mg/L for day 7 and 0.153 versus 0.052 mg/L
for day 28; not significant for either day 7 or day 28).
The surprising lack of association between ATG
levels and non-PTLD infections could be because of
the fact that the patients with the lowest ATG levels
developed GVHD and subsequently developed infec-
tions because of GVHD or its treatment. However,
when we excluded patients who developed grade II-
IV aGVHD or cGVHD NST from analysis, there
was also no significant difference in day 7 ATG levels
between patients who had no versus at least 1 infection
between day 7 and 28, day 7 and 56, or day 7 and 365 (n
5 62), and no significant difference in day 28 ATG
levels between patients who had no versus at least 1
infection between day 28 and 56, or day 28 and 365
(n 5 74) (data not shown). This was also true when
the analyses were done separately for microbiologi-
cally documented infections, viral infections, PTLD,
bacterial infections, and fungal infections.
We next set out to determine whether patients with
higher than cutoff ATG levels had a lower likelihood of
developing grade II-IV aGVHD or cGVHD NST or
higher likelihood of developing PTLD compared to
patients with lower than cutoff ATG levels. The results
are shown in Table 2 and Figure 3. ATG levels above
1.454 mg/L on day 7 were associated with 0.35-fold risk
of developing grade II-IV aGVHD (P5 0.030) and levels
above 0.029 mg/L on day 28 were associated with 0.52-
fold risk of developing grade II-IV aGVHD (P5 0.035).
Similarly, ATG levels above 0.803 mg/L on day 7 were
associated with 0.52-fold risk of developing cGVHD
NST (P 5 0.012) and levels above 0.052 mg/L on day
28 were associated with 0.60-fold risk of developing
cGVHD NST (P 5 0.028). ATG levels above 1.436
mg/L on day 7 were associated with 5.84-fold risk, and
above 0.082 mg/L on day 28 with 6.63-fold risk of devel-
oping PTLD (p 5 0.044 for day 7, p 5 0.015 for day
28). All patients who developed PTLD had ATG levelsabove 0.799 mg/L on day 7 and above 0.016 mg/L on
day 28; patientswith lower levels appeared tobeprotected.DISCUSSION
Here, we demonstrated that high levels of ATG on
day 7 and 28 predict a low likelihood of developing
aGVHDand cGVHDaswell as a high likelihood of de-
veloping PTLD. The association between ATG levels
and aGVHD has been previously noted by Remberger
and Sundberg [31]. However, the associations between
ATG levels and cGVHD and PTLD are new findings.
These were not described by Remberger and Sund-
berg[31], possibly because of their relatively small
sample size (n 5 76) or because they measured total
rabbit IgG (including both IgG that can bind to
lymphocytes as well as IgG that cannot). Consistent
with Remberger and Sundberg’s results, we also did
not observe any association between ATG levels and
relapse, death, nonrelapse death, or RFS. Neither Re-
mberger and Sundberg nor we were able to evaluate
potential impact of ATG levels on graft failure because
of its low occurrence. There appeared to be no impact
of high ATG levels on infections in our study; this was
not evaluated in the study of Remberger and
Sundberg.
The lack of associations between ATG levels and
relapse and non-PTLD infections should not be inter-
preted as ‘‘the lack of effect of ATG on relapse or non-
PTLD infections.’’ In studies using high dose (10-40
mg/kg thymoglobulin), but not in studies using low
dose (4-8 mg/kg thymoglobulin), there was a trend
toward higher relapse or non-PTLD infection rates
compared to no ATG controls [9,11,21,22,26,32,33].
Therefore, the effects of ATG may be dose-
dependent. Low-dose ATG may have anti-GVHD
and pro-PTLD effects only, whereas high-dose ATG
may have also pro-relapse and pro-viral/bacterial/
fungal infection effects. Thus, low-dose ATG might
partially protect against GVHDwithout adversely im-
pacting other outcomes like relapse or infection rates,
as long as PTLD incidence could be minimized.
Promising anti-PTLD strategies are emerging, for
example, preemptive (at the time of high/rising EBV
DNAemia) or prompt (early in the course of PTLD)
administration of rituximab [34-36] or EBV-specific
donor T cells [37-39].
Despite the fact that both aGVHD and cGVHD
incidences were lower in patients with higher ATG
levels, nonrelapse mortality (NRM) was not affected
by ATG levels. This may be because the anti-
GVHD effect was in part outweighed by the
pro-PTLD effect, or because ATG had no or minimal
effect on the most severe (fatal) aGVHD or cGVHD.
The latter is supported by the fact that ATG levels
were not lower in patients with aGVHD or
Figure 3. Cumulative incidence of grade II-IV acute GVHD, chronic GVHD NSTor PTLD in patients with day 7 or 28 ATG levels above or below the
cutoff specified in Table 2. Solid lines represent patients with ATG levels below the cutoff and broken lines patients with ATG levels above the cutoff.
P-values shown are adjusted for covariates (binomial regression multivariate analysis).
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(Table 2).
Serum half-life of ATG surmised from our median
levels on day 7 and 28 (5 days) is shorter than that
found in previous studies (1-6 weeks) [16,18,20-24].
Most of the previous studies measured total ATG, asopposed to us measuring ATG capable of binding to
lymphocytes. It is conceivable that the clearance of
antibodies capable of binding to lymphocytes may be
faster than the clearance of other antibodies
contained in ATG. Somewhat contrary to this
hypothesis, Kakhniashvili et al. [22] found that the
Table 2. Association (or lack of association) between ATG levels and clinical outcomes
ATG levels on day 7 n5 115 ATG levels on day 28 n5137
Median
ATG levels P value*
Cut- off
ATG level
Adjusted Relative
Risk (95% IC)
Adjusted
P value**
Median
ATG Levels P value*
Cut-off
ATG level
Adjusted Relative
Risk (95% IC)
Adjusted P
value**
Acute GVHD, any (grade 1-IV) Yes
No
1.030
1.293
0.181 0.718 0.64 (0.44-0.93) 0.030
0.071
0.008 0.021 0.61 (0.46-0.82) 0.001
Acute GVHD, grade II-IV Yes
No
0.781
1.364
0.019 1.454 0.35 (0.14-0.90) 0.030 0.025
0.066
0.002 0.029 0.52 (0.28-0.95) 0.035
Acute GVHD, grade III-IV Yes
No
1.030
1.133
0.240 0.022
0.055
0.152
Acute GVHD-related death Yes
No
1.034
1.125
0.835 0.007
0.053
0.300
Chronic GVHD, any (NNSTor NST‡) Yes
No
0.689
1.436
0.002 0.871 0.47 (0.31-0.73) 0.001 0.034
0.066
0.019 0.052 0.58 (0.41-0.85) 0.004
Chronic GVHD, NST‡ Yes
No
0.698
1.351
0.025 0.803 0.52 (0.32-0.87) 0.012 0.035
0.060
0.148 0.052 0.60 (0.39-0.95) 0.028
Chronic GVHD-related death Yes
No
1.865
1.091
0.177 0.106
0.053
0.477
Acute or chronic GVHD-related death Yes
No
1.455
1.109
0.357 0.055
0.053
0.893
Any infection (definite or presumed) § Yes
No
0.993
1.264
0.885 0.046
0.053
0.741
Definite infection§ Yes
No
0.927
1.243
0.998 0.046
0.053
0.768
Viral infection§ Yes
No
0.900
1.119
0.963 0.040
0.055
0.623
PTLD Yes
No
1.456
1.087
0.039 1.436 5.84 (1.81-18.87) 0.001 0.110
0.046
0.014 0.082 6.63 (1.51-29.08) 0.012
Bacterial Infection§ Yes
No
0.993
1.264
0.412 0.051
0.053
0.618
Fungal infection§ Yes
No
0.633
1.126
0.419 0.048
0.053
0.586
Severe infection§,† Yes
No
1.056
1.154
0.875 0.063
0.053
0.697
Severe definite infection§,† Yes
No
0.907
1.188
0.932 0.048
0.053
0.947
Relapse*** Yes
No
0.916
1.298
0.428 0.053
0.053
0.713
Relapse or death*** Yes
No
1.109
1.209
0.897 0.055
0.051
0.815
Death Yes
No
1.121
1.105
0.655 0.066
0.045
0.462
Death due to infection**** Yes
No
1.271
1.295
0.540 0.030
0.055
0.923
Non-relapse death**** Yes
No
1.337
1.087
0.721 0.055
0.053
0.800
*Mann-Whitney-Wilcoxon test (univariate analysis).
**Binomial regression (multivariate analysis).
§Yes indicates at least one infection between the time of ATG level determination (day 7 or 28) and day 365 post-transplant. PTLD is counted among any infections, definite infections, viral infections, severe infections
and severe definite infections.
†Severe infection was defined as an infection treated in a hospital. If an infection occurred during hospitalization for another reason, the infection was considered severe only if typically treated in the inpatient setting.
‡NNST indicates ‘‘not needing systemic therapy’’, NST indicates ‘‘needing systemic therapy.’’
***Patients with aplastic anemia (n53) were excluded from analysis.
****Patients who relapsed were excluded from analysis.
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924 Biol Blood Marrow Transplant 16:915-926, 2010P. J. Podgorny et al.rate of ATG disappearance from serum was similar for
antibodies capable of binding to lymphocytes and
antibodies capable of binding to granulocytes.
However, Kakhniashvili et al. [22] did not compare
antibodies capable of binding to lymphocytes versus
all other antibodies contained in ATG. In a mouse
study of rabbit-antimouse ATG (a model for
rabbit-antihuman ATG) it was shown that
lymphocyte-specific ATG is more rapidly cleared
from serum compared to total ATG [40]. This
supports the fact that the relatively short ATG half-
life in our study may be because of measuring only
the ATG capable of binding to lymphocytes. Another
reason for the relatively short half life in our study
could be the fact that we administered a relatively
low dose of ATG. It has been shown that the higher
the total ATG dose, the longer the half-life [20]. Yet
another reason for the relatively short half-life in our
study could be that we measured the disappearance
of ATGbetween day 7 and 28, that is, the time of a sub-
stantial increase of counts of leukocytes (including
lymphocytes) presumably adsorbing ATG from serum
(median leukocyte count of our patients was 0.1/nL on
day 7 and 4.9/nL on day 28, and median lymphocyte
count was 0.5/nL on day 28). In support of this
hypothesis, there was a significant correlation between
absolute lymphocyte count on day 28 and the change
of serum level of ATG (capable of binding lympho-
cytes) from day 7 to day 28 (Spearman rank correlation
coefficient r 5 0.302, P 5 .002).
What could be the reason for the large interpatient
variability in serum ATG levels after a uniform dose of
ATG (Figure 2)? One reason could be the variable
number of leukemic cells adsorbing ATG from serum;
this is unlikely, as when we compared the day 7 or day
28 ATG serum level or the change (day 28 minus day
7 level) between patients with acute leukemia in remis-
sion versus in relapse/refractory disease, there was no
significant difference (data not shown). Another reason
could be the variable number of cells infused with the
graft leading to a variable amount of ATG transferred
from serum to cells at the time of graft infusion.
Another reason could be the variable rate of leukocyte
recovery (see previous paragraph). Not only a variable
amount of ATGmay be transferred from the serum to
the recovering leukocytes, but also the rate of leuko-
cyte recovery may be a surrogate for the rate of recov-
ery of cells of the ‘‘reticuloendothelial system’’ where
antibodies are cleared [41]. In renal transplant recipi-
ents, the rate of disappearance from the serum was
increased when human-antirabbit antibodies were
detected [42]. Probably this is not the case in HCT
recipients, as HCT recipients cannot mount antibody
responses to neoantigens in the first month posttrans-
plant [43]. ATGmay bind to cells not only via Fab but
also via Fc. As human Fc receptors are polymorphic (in
some individuals binding therapeutic antibodies withhigh avidity and in others with low avidity [44]), it is
conceivable that interindividual variability in Fc recep-
tors may partly explain the interpatient variability in
ATG levels.
A limitation of our study is that we determined the
levels of rabbit IgG capable of binding to lymphocytes,
but not IgG capable of binding to lymphocyte subsets
or other immune cell subsets, or IgG exerting a specific
function like inducing differentiation of CD4 T cells
into regulatory cells or blocking proliferation or
chemotaxis of T cells or other immune cells. Further
studies could attempt to determine whether the anti-
GVHD or pro-PTLD effect of ATG is associated
with its ability to bind to a specific immune cell subset
or to inhibit a specific immune cell function. If yes, this
would give insight into the mechanism of action of
ATG and facilitate its further improvement (eg, by
depleting the pro-PTLD IgG fraction or enriching
for the anti-GVHD IgG fraction).
Our conclusions regardingGVHDare imperfect, as
we used historical definitions of aGVHD and cGVHD
(before/after day 100). Moreover, instead of the NIH
grading of cGVHD [45] we used a treatment-based
classification (NNST, roughly corresponding to
mild cGVHD, and NST, roughly corresponding to
moderate or severe cGVHD per the NIH grading).
Given the highly variable clearance of ATG, could
it be beneficial to give an additional dose of ATG to
patients with low levels on day 7? In a study randomiz-
ing patients, who received 7.5mg/kg ATGduring con-
ditioning, to no ATG versus 2.5-3.75 mg/kg ATG on
day 7, there was no survival difference, but the inci-
dences of both aGVHD and cGVHD were reduced,
so presumably patient quality of life was improved
[46]. Perhaps a survival difference or a greater reduc-
tion of the GVHD incidences could have been
achieved if ATG was administered on day 7 only to
patients with low day 7 ATG levels.
In conclusion, low-dose ATGhas anti-GVHD and
pro-PTLD effects, but probably no effect on relapse or
non-PTLD infections. Research into optimization of
transplant outcomes using ATG should include
ATG dosing based on its pharmacokinetics and anti-
PTLD strategies like preemptive/prompt infusion of
rituximab or EBV-specific T cells.ACKNOWLEDGMENTS
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